I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy 2018-11-02 21:11
First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT) 2018-10-12 14:01
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs 2018-09-26 21:27
I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)" 2018-09-19 15:33
I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes 2018-08-09 16:16
I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202 2018-08-08 09:01
I-Mab Biopharma Announces New CFO 2018-08-01 08:44
I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies 2018-07-26 21:30
I-Mab Successfully Raised USD 220 Million in Series C Funding 2018-06-29 18:36
I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine 2017-12-25 19:50
I-Mab Biopharma Partners with MorphoSys on Cancer Investigational Medicine 2017-12-01 15:55
1 5 6 7 8 9